10-Q: Profusa Inc. Q2 2026: Mounting Losses, Nasdaq Scrutiny, and Acquisition Pursuits

Profusa Inc. reported substantial net losses for Q2 2026, continued operational challenges including Nasdaq listing concerns, and significant ongoing debt, while pursuing strategic acquisitions.

Summary

• Profusa, Inc. reported a net loss of $8.8 million for the three months ended June 30, 2026, and $12.2 million for the six months ended June 30, 2026.
• The company has a working capital deficit of approximately $27.3 million as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• Profusa is working to regain compliance with Nasdaq listing requirements, having transferred to The Nasdaq Capital Market.
• The company is pursuing strategic acquisitions, including an option agreement for G3 Vision Labs Inc. and its subsidiaries.
• Significant financing activities include draws under the ELOC and PIPE Subscription Agreement, and various debt instruments.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, substantial doubt about the company's ability to continue as a going concern, and continued reliance on external financing, despite some recent strategic developments.

Positives

• The company received approval for the forgiveness of its $1.4 million PPP loan.
• Profusa obtained regulatory approval in Europe for its Lumee Oxygen platform (CE mark), though it lapsed and is being renewed.
• The company entered into a know-how license agreement with Mayo Clinic for continuous oxygen measurement and critical limb-threatening ischemia.
• An option agreement was entered into for the potential acquisition of G3 Vision Labs Inc. and its subsidiaries, expanding into health diagnostics and toxicology testing.
• The company has access to up to $100.0 million under an Equity Line of Credit (ELOC) with Ascent.

Negatives

• Net loss for the three months ended June 30, 2026, was $8.8 million, and $12.2 million for the six months ended June 30, 2026.
• The company has a working capital deficit of $27.3 million as of June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Operating expenses increased significantly, with R&D up 109% and G&A up 182% for the three months ended June 30, 2026, compared to the prior year.
• The company is subject to Nasdaq continued listing requirements and has transferred to The Nasdaq Capital Market.
• Significant debt obligations remain, with $14.0 million due within twelve months as of June 30, 2026.
• The company implemented a reduction in force, decreasing its workforce from 11 to 5 employees.

Risks

• The company's ability to obtain future financing is critical, as it has incurred recurring losses and expects to continue doing so.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company is subject to Nasdaq continued listing standards and faces potential delisting if compliance is not maintained.
• The proposed acquisition of G3 Vision Labs Inc. is subject to numerous conditions, including significant financing requirements, and may not be completed.
• Integration of G3 and its subsidiaries, if acquired, presents significant challenges due to different market focus and limited experience.
• The company's success depends on the continued services of its executive officers and key employees, and competition for qualified personnel is intense.
• Warrants issued in connection with debt financing may result in significant dilution to existing stockholders.
• The company's products require regulatory approval (FDA, CE mark), and there is no assurance that such approvals will be obtained or maintained.

Future Outlook

The company expects to continue incurring substantial losses and requires additional financing to fund operations, product commercialization, and research and development. Future capital needs are expected to be met through equity or debt financing. The company anticipates Lumee Glucose launch in 2026, subject to regulatory approval, and Lumee Oxygen commercialization in Europe in 2027.

Management Comments

• Management expects to continue to incur additional substantial losses in the foreseeable future as a result of research and development activities.
• Additional funds may be necessary to maintain current operations and will be required for successful product commercialization efforts.
• Conditions exist that raise substantial doubt about our ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive and rapidly evolving medical technology and digital health sectors, focusing on continuous monitoring solutions. The company's progress in developing its Lumee Glucose and Lumee Oxygen platforms, alongside its pursuit of regulatory approvals and strategic acquisitions, aligns with broader industry trends towards personalized medicine and remote patient monitoring. However, the significant financial losses and ongoing need for capital highlight the high-risk, high-reward nature of this sector.

Comparison to Industry Standards

• The company's net loss of $12.2 million for the first six months of 2026 and a working capital deficit of $27.3 million indicate a significant cash burn rate, which is common for early-stage medical technology companies but requires substantial and continuous funding.
• The pursuit of regulatory approvals (CE mark, FDA clearance) is a standard but lengthy and costly process in the medical device industry.
• The company's reliance on equity and debt financing, including an ELOC and PIPE financing, is typical for companies in this stage, but the substantial outstanding debt and potential for dilution are key considerations.
• The company's focus on continuous glucose monitoring (CGM) places it in a market with established players like Dexcom and Abbott, requiring significant differentiation and market penetration strategies.

Management Changes

Legal Proceedings

• The company had accrued approximately $0.1 million related to a vendor litigation where judgment was entered in favor of the vendor.
• A demand letter was received from counsel for a former employee for unpaid wages of approximately $0.2 million, including statutory penalties.

Related Party Transactions

• The company has outstanding convertible notes payable to related parties, including Tasly Convertible Note ($2.6 million as of June 30, 2026) and Convertible Promissory Note - Related Party ($2.1 million as of June 30, 2026).
• There is an outstanding amount of $41,000 due to related party for an administrative service fee.
• Related party interest expense was $5 thousand for the three months ended June 30, 2026, and $10 thousand for the six months ended June 30, 2026.

Stakeholder Impact

• Existing stockholders face potential significant dilution from the exercise of warrants and conversion of preferred stock.
• The company's ability to continue as a going concern may impact the value of common stock and the likelihood of future returns for shareholders.
• Employees may be impacted by the reduction in force and the uncertainty surrounding the company's financial stability.
• Creditors and debt holders face risks related to the company's ability to meet its debt obligations, given its current financial condition.

Next Steps

• Obtain a renewed CE Mark for commercialization in Europe for Lumee Oxygen.
• Obtain FDA clearance or approval for Lumee Oxygen in the U.S.
• Launch Lumee Glucose, expected in 2026, subject to regulatory approval.
• Complete due diligence and negotiate definitive agreements for the proposed acquisition of G3 Vision Labs Inc.
• Demonstrate compliance with Nasdaq continued listing standards.
• Continue to fund operations and product commercialization efforts through additional financing.

Key Dates

Recommendation

Profusa Inc. is in a highly speculative, clinical-stage with significant financial challenges, including substantial losses and going concern doubts. While there are promising technological developments and strategic acquisition pursuits, the path to profitability and sustainable operations remains uncertain and heavily reliant on future financing and regulatory approvals. The current situation warrants a 'hold' recommendation, advising investors to monitor progress closely, particularly regarding financing, Nasdaq compliance, and acquisition outcomes, before considering any further investment.

Keywords

biosensing, continuous glucose monitor, tissue oxygen monitoring, medical technology, digital health, biocompatible gel, clinical stage, regulatory approval